company background image
A298

ABL Bio KOSDAQ:A298380 Stock Report

Last Price

₩21.45k

Market Cap

₩1.0t

7D

4.4%

1Y

0.7%

Updated

16 May, 2022

Data

Company Financials
A298380 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

A298380 Stock Overview

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.

ABL Bio Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for ABL Bio
Historical stock prices
Current Share Price₩21,450.00
52 Week High₩34,800.00
52 Week Low₩17,500.00
Beta1.06
1 Month Change-15.05%
3 Month Change-17.34%
1 Year Change0.70%
3 Year Change-30.58%
5 Year Changen/a
Change since IPO57.14%

Recent News & Updates

Mar 31
We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jan 20
Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

We believe investing is smart because history shows that stock markets go higher in the long term. But not every stock...

Dec 16
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

A298380KR BiotechsKR Market
7D4.4%-2.8%0.006%
1Y0.7%-39.8%-15.8%

Return vs Industry: A298380 exceeded the KR Biotechs industry which returned -38.1% over the past year.

Return vs Market: A298380 exceeded the KR Market which returned -15.2% over the past year.

Price Volatility

Is A298380's price volatile compared to industry and market?
A298380 volatility
A298380 Average Weekly Movement9.4%
Biotechs Industry Average Movement6.4%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.3%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A298380 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: A298380's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSang Hoon Leehttps://www.ablbio.com

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam, South Korea.

ABL Bio Fundamentals Summary

How do ABL Bio's earnings and revenue compare to its market cap?
A298380 fundamental statistics
Market Cap₩1.02t
Earnings (TTM)-₩43.56b
Revenue (TTM)₩5.33b

191.6x

P/S Ratio

-23.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A298380 income statement (TTM)
Revenue₩5.33b
Cost of Revenue₩47.98m
Gross Profit₩5.28b
Other Expenses₩48.84b
Earnings-₩43.56b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-914.78
Gross Margin99.10%
Net Profit Margin-816.91%
Debt/Equity Ratio0%

How did A298380 perform over the long term?

See historical performance and comparison

Valuation

Is ABL Bio undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


18.25x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A298380's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A298380's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A298380 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.

PE vs Market: A298380 is unprofitable, so we can't compare its PE Ratio to the KR market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A298380's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A298380 is overvalued based on its PB Ratio (18.3x) compared to the KR Biotechs industry average (3.3x).


Future Growth

How is ABL Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ABL Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has ABL Bio performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


35.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A298380 is currently unprofitable.

Growing Profit Margin: A298380 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A298380 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.2% per year.

Accelerating Growth: Unable to compare A298380's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A298380 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).


Return on Equity

High ROE: A298380 has a negative Return on Equity (-77.85%), as it is currently unprofitable.


Financial Health

How is ABL Bio's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A298380's short term assets (₩45.5B) exceed its short term liabilities (₩8.8B).

Long Term Liabilities: A298380's short term assets (₩45.5B) exceed its long term liabilities (₩749.4M).


Debt to Equity History and Analysis

Debt Level: A298380 is debt free.

Reducing Debt: A298380 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A298380 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A298380 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.7% each year


Dividend

What is ABL Bio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A298380's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A298380's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A298380's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A298380's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A298380 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Sang Hoon Lee

6.33yrs

Tenure

Dr. Sang Hoon Lee, PH D co-founded PharmAbcine, Inc. in 2008 and serves as its Executive Vice President. Dr. Lee founded ABL Bio Inc. in February 2016 and serves as its President and Chief Executive Office...


Leadership Team

Experienced Management: A298380's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ABL Bio Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ABL Bio Inc.
  • Ticker: A298380
  • Exchange: KOSDAQ
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩1.021t
  • Shares outstanding: 47.62m
  • Website: https://www.ablbio.com

Location

  • ABL Bio Inc.
  • 16 Daewangpangyo-Ro 712 Beon-Gil
  • 2nd Floor
  • Seongnam-si
  • Gyeonggi-do
  • 13488
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.